MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

0.95 -67.69

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.95

Max

0.95

Galvenie mērījumi
By Trading Economics
Ienākumi	183K -27M
Darbinieki	166
EBITDA	9.4M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+122.97% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	157M 252M
Iepriekšējā atvēršanas cena	68.64
Iepriekšējā slēgšanas cena	0.95

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. janv. 16:17 UTC

Iegādes, apvienošanās, pārņemšana

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

2026. g. 19. janv. 23:50 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

2026. g. 19. janv. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026. g. 19. janv. 22:29 UTC

Tirgus saruna

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

2026. g. 19. janv. 22:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 19. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 19. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 19. janv. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 19. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 19. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 19. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 19. janv. 17:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 19. janv. 17:09 UTC

Tirgus saruna

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

2026. g. 19. janv. 16:18 UTC

Tirgus saruna

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

2026. g. 19. janv. 16:12 UTC

Tirgus saruna

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

2026. g. 19. janv. 16:06 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

2026. g. 19. janv. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

2026. g. 19. janv. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

LVMH, CTG Duty-Free Also Entered Into a MoU

2026. g. 19. janv. 16:02 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Subscription to Be Made Upon Completion of Transaction

2026. g. 19. janv. 16:00 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

2026. g. 19. janv. 16:00 UTC

Tirgus saruna

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

2026. g. 19. janv. 15:58 UTC

Iegādes, apvienošanās, pārņemšana

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

2026. g. 19. janv. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

2026. g. 19. janv. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Proceeds of Transaction Will Be Paid in Cash

2026. g. 19. janv. 15:56 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

2026. g. 19. janv. 15:53 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

2026. g. 19. janv. 15:52 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

2026. g. 19. janv. 15:51 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

2026. g. 19. janv. 15:39 UTC

Tirgus saruna

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

2026. g. 19. janv. 15:37 UTC

Tirgus saruna

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

122.97% augšup

Prognoze 12 mēnešiem

Vidējais 6.6 USD 122.97%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.